Codexis, Inc. (NASDAQ:CDXS) Stock Holdings Lifted by Telemark Asset Management LLC

Telemark Asset Management LLC increased its stake in shares of Codexis, Inc. (NASDAQ:CDXS) by 11.3% in the 4th quarter, HoldingsChannel.com reports. The firm owned 3,000,000 shares of the biotechnology company’s stock after buying an additional 303,589 shares during the quarter. Codexis comprises approximately 1.4% of Telemark Asset Management LLC’s portfolio, making the stock its 23rd largest holding. Telemark Asset Management LLC’s holdings in Codexis were worth $14,310,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Intech Investment Management LLC acquired a new stake in shares of Codexis during the third quarter worth approximately $66,000. Kingswood Wealth Advisors LLC acquired a new stake in shares of Codexis during the fourth quarter worth approximately $79,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Codexis during the fourth quarter worth approximately $82,000. Jackson Square Capital LLC acquired a new stake in shares of Codexis during the fourth quarter worth approximately $210,000. Finally, GSA Capital Partners LLP boosted its holdings in shares of Codexis by 83.5% during the third quarter. GSA Capital Partners LLP now owns 99,629 shares of the biotechnology company’s stock worth $307,000 after purchasing an additional 45,337 shares during the period. 78.54% of the stock is currently owned by institutional investors and hedge funds.

Codexis Stock Performance

CDXS stock opened at $2.76 on Thursday. The company has a quick ratio of 3.15, a current ratio of 3.21 and a debt-to-equity ratio of 0.39. The company has a market capitalization of $228.63 million, a price-to-earnings ratio of -3.17 and a beta of 2.12. Codexis, Inc. has a 12 month low of $2.47 and a 12 month high of $6.08. The firm has a 50 day moving average of $4.21 and a two-hundred day moving average of $3.95.

Codexis (NASDAQ:CDXS) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.04) by ($0.09). The firm had revenue of $21.46 million for the quarter, compared to the consensus estimate of $27.41 million. Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. As a group, equities analysts anticipate that Codexis, Inc. will post -0.77 EPS for the current fiscal year.

Analyst Ratings Changes

Separately, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price target on shares of Codexis in a report on Friday, November 22nd.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.